Clinical Trial Update: Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial of itacitinib for treating steroid-refractory immune-related adverse events from immune checkpoint inhibitors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Solid Tumor

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Douglas Johnson | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Status: WITHDRAWN